Get started
Author

Laura von Schantz

Observed names: L. Schantz, L. von Schantz, Laura Von Schantz, Schantz, Laura, von Schantz, Laura
ORCID: 0000-0003-1236-3135
Observed ORCID: 0000-0003-1236-3135
OpenAlex ID: A5072019967
Versatile High Resolution Oligosaccharide Microarrays for Plant Glycobiology and Cell Wall Research
2012 · Henriette L. Pedersen, Jonatan U. Fangel, et al. · Journal of Biological Chemistry · 283
PDF
The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation
2019 · Anne Månsson Kvarnhammar, Niina Veitonmäki, et al. · Journal for ImmunoTherapy of Cancer · 122
PDF
Structural basis for carbohydrate-binding specificity—A comparative assessment of two engineered carbohydrate-binding modules
2012 · Laura von Schantz, Maria Håkansson, et al. · Glycobiology · 37
Affinity maturation generates greatly improved xyloglucan-specific carbohydrate binding modules
2009 · Laura von Schantz, Fredrika Gullfot, et al. · BMC Biotechnology · 36
PDF
Bispecific antibodies targeting CD40 and tumor-associated antigens promote cross-priming of T cells resulting in an antitumor response superior to monospecific antibodies
2022 · Karin Hägerbrand, Laura Varas, et al. · Journal for ImmunoTherapy of Cancer · 34
PDF
Characterization of the substitution pattern of cellulose derivatives using carbohydrate-binding modules
2014 · Laura von Schantz, Herje Schagerlöf, et al. · BMC Biotechnology · 33
PDF
Microdistribution of xyloglucan in differentiating poplar cells
2010 · David Sandquist, Lada Filonova, et al. · BioResources · 27
PDF
Carbohydrate binding module recognition of xyloglucan defined by polar contacts with branching xyloses and CH ‐Π interactions
2014 · Laura von Schantz, Maria Håkansson, et al. · Proteins Structure Function and Bioinformatics · 19
Neutron Crystallographic Studies Reveal Hydrogen Bond and Water-Mediated Interactions between a Carbohydrate-Binding Module and Its Bound Carbohydrate Ligand
2015 · S. Zoë Fisher, Laura von Schantz, et al. · Biochemistry · 17
The crystal structure of XG‐34, an evolved xyloglucan‐specific carbohydrate‐binding module
2009 · Fredrika Gullfot, Tien‐Chye Tan, et al. · Proteins Structure Function and Bioinformatics · 16
The Bispecific Tumor Antigen-Conditional 4–1BB x 5T4 Agonist, ALG.APV-527, Mediates Strong T-Cell Activation and Potent Antitumor Activity in Preclinical Studies
2022 · Michelle H. Nelson, Sara Fritzell, et al. · Molecular Cancer Therapeutics · 12
Bioinspired assemblies of plant cell wall polymers unravel the affinity properties of carbohydrate-binding modules
2015 · Gabriel Paës, Laura von Schantz, et al. · Soft Matter · 11
ATOR-1017 (evunzekibart), an Fc-gamma receptor conditional 4-1BB agonist designed for optimal safety and efficacy, activates exhausted T cells in combination with anti-PD-1
2023 · Karin Enell Smith, Sara Fritzell, et al. · Cancer Immunology Immunotherapy · 10
PDF
RUBY® – a tetravalent (2+2) bispecific antibody format with excellent functionality and IgG-like stability, pharmacology and developability properties
2024 · Barnabas Nyesiga, Mattias Levin, et al. · mAbs · 9
PDF
Crystallization, neutron data collection, initial structure refinement and analysis of a xyloglucan heptamer bound to an engineered carbohydrate-binding module from xylanase
2015 · Mats Ohlin, Laura von Schantz, et al. · Acta Crystallographica Section F Structural Biology Communications · 6
PDF
858 A bispecific antibody targeting CD40 and EpCAM induces superior anti-tumor effects compared to the combination of the monospecific antibodies
2020 · Peter Ellmark, Karin Hägerbrand, et al. · Journal for ImmunoTherapy of Cancer · 5
Antigenic peptide delivery to antigen-presenting cells using a CD40-coiled coil affinity-based platform
2025 · Barnabas Nyesiga, Karin Hägerbrand, et al. · Drug Delivery · 4
PDF
751 Neo-X-Prime bispecific antibodies targeting CD40 and tumor antigens promote cross-presentation of tumor exosome-derived neoantigen and induce superior anti-tumor responses compared to CD40 mAb
2021 · Karin Hagerbrand, Mattias Levin, et al. · Journal for ImmunoTherapy of Cancer · 2
PDF
ATOR-4066, a Bispecific Antibody Targeting CD40 and CEACAM5, Induces Strong Myeloid and T Cell–Dependent Tumor Immunity and Synergizes with PD-1 Blockade
2025 · Hampus Andersson, Ida Uddbäck, et al. · Cancer Immunology Research · 1
PDF
Activation of the CD137 Pathway in T cells by a CD137 × 5T4 bispecific ADAPTIR Molecule Requires Co-engagement of CD137 and 5T4
2018 · Gabriele R Blahnik-Fagan, Robert Bader, et al. · The Journal of Immunology · 1
Data from ATOR-4066, a Bispecific Antibody Targeting CD40 and CEACAM5, Induces Strong Myeloid and T Cell–Dependent Tumor Immunity and Synergizes with PD-1 Blockade
2025 · Hampus Andersson, Ida Uddbäck, et al.
Supplementary Figure S1 from ATOR-4066, a Bispecific Antibody Targeting CD40 and CEACAM5, Induces Strong Myeloid and T Cell–Dependent Tumor Immunity and Synergizes with PD-1 Blockade
2025 · Hampus Andersson, Ida Uddbäck, et al.
Supplementary Figure S17 from ATOR-4066, a Bispecific Antibody Targeting CD40 and CEACAM5, Induces Strong Myeloid and T Cell–Dependent Tumor Immunity and Synergizes with PD-1 Blockade
2025 · Hampus Andersson, Ida Uddbäck, et al.
Supplementary Figure S15 from ATOR-4066, a Bispecific Antibody Targeting CD40 and CEACAM5, Induces Strong Myeloid and T Cell–Dependent Tumor Immunity and Synergizes with PD-1 Blockade
2025 · Hampus Andersson, Ida Uddbäck, et al.
Supplementary Table S2 from ATOR-4066, a Bispecific Antibody Targeting CD40 and CEACAM5, Induces Strong Myeloid and T Cell–Dependent Tumor Immunity and Synergizes with PD-1 Blockade
2025 · Hampus Andersson, Ida Uddbäck, et al.
Works count: 74
Citation count: 685
H-index: 11
I10-index: 13
Year
Topic
Type